日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design

利用计算机辅助药物设计发现SARS-CoV-2主蛋白酶的高效非共价抑制剂

Okabe, Atsutoshi; Carney, Daniel W; Tawada, Michiko; Akther, Thamina; Aida, Jumpei; Takagi, Terufumi; Dougan, Douglas R; Leffler, Abba E; Bell, Jeffrey A; Frye, Leah; Hickey, Eugene R; Komandla, Mallareddy; Tao, Will; Selimkhanov, Jangir; Yonemori, Kazuko; Chang, Edcon; Saikatendu, Kumar; Ochida, Atsuko

Repurposing of the RIPK1-Selective Benzo[1,4]oxazepin-4-one Scaffold for the Development of a Type III LIMK1/2 Inhibitor.

RIPK1 选择性苯并[1,4]氧氮杂环庚酮-4-酮骨架的再利用,用于开发 III 型 LIMK1/2 抑制剂

Mandel Sebastian, Hanke Thomas, Mathea Sebastian, Chatterjee Deep, Saraswati Hayuningbudi, Berger Benedict-Tilman, Schwalm Martin Peter, Yamamoto Satoshi, Tawada Michiko, Takagi Terufumi, Ahmed Mahmood, Röhm Sandra, Corrionero Ana, Alfonso Patricia, Baena Maria, Elson Lewis, Menge Amelie, Krämer Andreas, Pereira Raquel, Müller Susanne, Krause Daniela S, Knapp Stefan

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

发现一系列新型高效、选择性强、口服有效且能穿透血脑屏障的C1s抑制剂,用于调节补体途径

Ikeda Zenichi, Kamei Taku, Sasaki Yusuke, Reynolds Matthew, Sakai Nozomu, Yoshikawa Masato, Tawada Michiko, Morishita Nao, Dougan Douglas R, Chen Chien-Hung, Levin Irena, Zou Hua, Kuno Masako, Arimura Naoto, Kikukawa Yusuke, Kondo Mitsuyo, Tohyama Kimio, Sato Kenjiro